SpringerLink
Log in

Ubiquitylation - Dependent Signaling in Heart Disease

  • Chapter
  • First Online:
Translational Cardiology

Part of the book series: Molecular and Translational Medicine ((MOLEMED))

  • 1034 Accesses

Abstract

The regulation of cell signaling by posttranslational phosphorylation of proteins has emerged as a major mechanism by which external ligands regulate cell function. Like phosphorylation, modifying proteins with ubiquitin can regulate a number of ever-expanding cellular functions such as cell growth, apoptosis, the innate immune response, and proteins that regulate responses to DNA damage. In this chapter we review recently published findings implicating the ubiquitin proteasome system (UPS) in regulating key signal transduction pathways and transcription factors in the heart, including MAPK JNK, calcineurin, FOXO, p53, estrogen receptors α and β, NF-κB, and SMAD. We then discuss how regulation of these signal transduction pathways by the UPS plays a role in common cardiac diseases, including cardiac hypertrophy, heart failure, ischemia reperfusion injury, myocardial infarction, and diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
EUR 29.95
Price includes VAT (Germany)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
EUR 128.39
Price includes VAT (Germany)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
EUR 165.84
Price includes VAT (Germany)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
EUR 213.99
Price includes VAT (Germany)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Raiborg C, Stenmark H. The ESCRT machinery in endosomal sorting of ubiquitylate membrane proteins. Nature. 2009;458(7237):445–52.

    PubMed  CAS  Google Scholar 

  2. Bhoj VG, Chen ZJ. Ubiquitylation in innate and adaptive immunity. Nature. 2009;458(7237):430–7.

    PubMed  CAS  Google Scholar 

  3. Hofmann RM, Pickart CM. In vitro assembly and recognition of Lys-63 polyubiquitin chains. J Biol Chem. 2001;276(30):27936–43.

    PubMed  CAS  Google Scholar 

  4. Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature. 2009;458(7237):438–44.

    PubMed  CAS  Google Scholar 

  5. Greenwood DD. Critical bandwidth and consonance in relation to cochlear frequency-position coordinates. Hear Res. 1991;54(2):164–208.

    PubMed  CAS  Google Scholar 

  6. Heemers HV, Tindall DJ. Unraveling the complexities of androgen receptor signaling in prostate cancer cells. Cancer Cell. 2009;15(4):245–7.

    PubMed  CAS  Google Scholar 

  7. Ikeda F, Dikic I. Atypical ubiquitin chains: new molecular signals. ‘Protein Modifications: Beyond the Usual Suspects’ review series. EMBO Rep. 2008;9(6):536–42.

    PubMed  CAS  Google Scholar 

  8. Hicke L. Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol. 2001;2(3):195–201.

    PubMed  CAS  Google Scholar 

  9. Trotman LC, Wang X, Alimonti A, et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell. 2007;128(1):141–56.

    PubMed  CAS  Google Scholar 

  10. Hicke L. Gettin’ down with ubiquitin: turning off cell-surface receptors, transporters and channels. Trends Cell Biol. 1999;9(3):107–12.

    PubMed  CAS  Google Scholar 

  11. Bogoyevitch MA, Gillespie-Brown J, Ketterman AJ, et al. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circ Res. 1996;79(2):162–73.

    PubMed  CAS  Google Scholar 

  12. Petrich BG, Molkentin JD, Wang Y. Temporal activation of c-Jun N-terminal kinase in adult transgenic heart via cre-loxP-mediated DNA recombination. FASEB J. 2003;17(6):749–51.

    PubMed  CAS  Google Scholar 

  13. Goldsmith ZG, Dhanasekaran DN. G protein regulation of MAPK networks. Oncogene. 2007;26(22):3122–42.

    PubMed  CAS  Google Scholar 

  14. Pandur P, Maurus D, Kuhl M. Increasingly complex: new players enter the Wnt signaling network. Bioessays. 2002;24(10):881–4.

    PubMed  CAS  Google Scholar 

  15. Rose BA, Force T, Wang Y. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev. 2010;90(4):1507–46.

    PubMed  CAS  Google Scholar 

  16. Laderoute KR, Webster KA. Hypoxia/reoxygenation stimulates Jun kinase activity through redox signaling in cardiac myocytes. Circ Res. 1997;80(3):336–44.

    PubMed  CAS  Google Scholar 

  17. Hirsch DD, Stork PJ. Mitogen-activated protein kinase phosphatases inactivate stress-activated protein kinase pathways in vivo. J Biol Chem. 1997;272(7):4568–75.

    PubMed  CAS  Google Scholar 

  18. Bermudez O, Pages G, Gimond C. The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am J Physiol Cell Physiol. 2010;299(2):C189–202.

    PubMed  CAS  Google Scholar 

  19. Patterson KI, Brummer T, O’Brien PM, Daly RJ. Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J. 2009;418(3):475–89.

    PubMed  CAS  Google Scholar 

  20. Laine A, Ronai Z. Ubiquitin chains in the ladder of MAPK signaling. Sci STKE. 2005;2005(281):re5.

    PubMed  Google Scholar 

  21. Guo B, Yang SH, Witty J, Sharrocks AD. Signalling pathways and the regulation of SUMO modification. Biochem Soc Trans. 2007;35(Pt 6):1414–8.

    PubMed  CAS  Google Scholar 

  22. Yang SH, Sharrocks AD. Convergence of the SUMO and MAPK pathways on the ETS-domain transcription factor Elk-1. Biochem Soc Symp. 2006;73:121–9.

    PubMed  CAS  Google Scholar 

  23. **a Y, Wang J, Xu S, Johnson GL, Hunter T, Lu Z. MEKK1 mediates the ubiquitination and degradation of c-Jun in response to osmotic stress. Mol Cell Biol. 2007;27(2):510–7.

    PubMed  CAS  Google Scholar 

  24. Lu Z, Xu S, Joazeiro C, Cobb MH, Hunter T. The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2. Mol Cell. 2002;9(5):945–56.

    PubMed  CAS  Google Scholar 

  25. Nateri AS, Riera-Sans L, Da Costa C, Behrens A. The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. Science. 2004;303(5662):1374–8.

    PubMed  CAS  Google Scholar 

  26. Li HH, Du J, Fan YN, et al. The ubiquitin ligase MuRF1 protects against cardiac ischemia/reperfusion injury by its proteasome-dependent degradation of phospho-c-Jun. Am J Pathol. 2011;178(3):1043–58.

    PubMed  CAS  Google Scholar 

  27. **e P, Guo S, Fan Y, Zhang H, Gu D, Li H. Atrogin-1/MAFbx enhances simulated ischemia/reperfusion-induced apoptosis in cardiomyocytes through degradation of MAPK phosphatase-1 and sustained JNK activation. J Biol Chem. 2009;284(9):5488–96.

    PubMed  CAS  Google Scholar 

  28. Dickens M, Rogers JS, Cavanagh J, et al. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science. 1997;277(5326):693–6.

    PubMed  CAS  Google Scholar 

  29. Whitmarsh AJ, Cavanagh J, Tournier C, Yasuda J, Davis RJ. A mammalian scaffold complex that selectively mediates MAP kinase activation. Science. 1998;281(5383):1671–4.

    PubMed  CAS  Google Scholar 

  30. Wang J. Cardiac function and disease: emerging role of small ubiquitin-related modifier. Wiley Interdiscip Rev Syst Biol Med. 2011;3(4):446–57.

    PubMed  CAS  Google Scholar 

  31. Muller S, Berger M, Lehembre F, Seeler JS, Haupt Y, Dejean A. c-Jun and p53 activity is modulated by SUMO-1 modification. J Biol Chem. 2000;275(18):13321–9.

    PubMed  CAS  Google Scholar 

  32. Sugden PH, Clerk A. “Stress-responsive” mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res. 1998;83(4):345–52.

    PubMed  CAS  Google Scholar 

  33. Yin T, Sandhu G, Wolfgang CD, et al. Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney. J Biol Chem. 1997;272(32):19943–50.

    PubMed  CAS  Google Scholar 

  34. Hreniuk D, Garay M, Gaarde W, Monia BP, McKay RA, Cioffi CL. Inhibition of c-Jun N-terminal kinase 1, but not c-Jun N-terminal kinase 2, suppresses apoptosis induced by ischemia/reoxygenation in rat cardiac myocytes. Mol Pharmacol. 2001;59(4):867–74.

    PubMed  CAS  Google Scholar 

  35. Knight RJ, Buxton DB. Stimulation of c-Jun kinase and mitogen-activated protein kinase by ischemia and reperfusion in the perfused rat heart. Biochem Biophys Res Commun. 1996;218(1):83–8.

    PubMed  CAS  Google Scholar 

  36. Clerk A, Fuller SJ, Michael A, Sugden PH. Stimulation of “stress-regulated” mitogen-activated protein kinases (stress-activated protein kinases/c-Jun N-terminal kinases and p38-mitogen-activated protein kinases) in perfused rat hearts by oxidative and other stresses. J Biol Chem. 1998;273(13):7228–34.

    PubMed  CAS  Google Scholar 

  37. Klee CB, Crouch TH, Krinks MH. Calcineurin: a calcium- and calmodulin-binding protein of the nervous system. Proc Natl Acad Sci USA. 1979;76(12):6270–3.

    PubMed  CAS  Google Scholar 

  38. MacDonnell SM, Weisser-Thomas J, Kubo H, et al. CaMKII negatively regulates calcineurin-NFAT signaling in cardiac myocytes. Circ Res. 2009;105(4):316–25.

    PubMed  CAS  Google Scholar 

  39. Stefan MI, Edelstein SJ, Le Novere N. An allosteric model of calmodulin explains differential activation of PP2B and CaMKII. Proc Natl Acad Sci USA. 2008;105(31):10768–73.

    PubMed  CAS  Google Scholar 

  40. Okamura H, Aramburu J, Garcia-Rodriguez C, et al. Concerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activity. Mol Cell. 2000;6(3):539–50.

    PubMed  CAS  Google Scholar 

  41. Suzuki E, Nishimatsu H, Satonaka H, et al. Angiotensin II induces myocyte enhancer factor 2- and calcineurin/nuclear factor of activated T cell-dependent transcriptional activation in vascular myocytes. Circ Res. 2002;90(9):1004–11.

    PubMed  CAS  Google Scholar 

  42. Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93(2):215–28.

    PubMed  CAS  Google Scholar 

  43. Chin ER, Olson EN, Richardson JA, et al. A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev. 1998;12(16):2499–509.

    PubMed  CAS  Google Scholar 

  44. Li HH, Willis MS, Lockyer P, et al. Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins. J Clin Invest. 2007;117(11):3211–23.

    PubMed  CAS  Google Scholar 

  45. Li HH, Kedar V, Zhang C, et al. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J Clin Invest. 2004;114(8):1058–71.

    PubMed  CAS  Google Scholar 

  46. Tang M, Li J, Huang W, et al. Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts. Cardiovasc Res. 2010;88(3):424–33.

    PubMed  CAS  Google Scholar 

  47. Gwack Y, Sharma S, Nardone J, et al. A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT. Nature. 2006;441(7093):646–50.

    PubMed  CAS  Google Scholar 

  48. Okamura H, Garcia-Rodriguez C, Martinson H, Qin J, Virshup DM, Rao A. A conserved docking motif for CK1 binding controls the nuclear localization of NFAT1. Mol Cell Biol. 2004;24(10):4184–95.

    PubMed  CAS  Google Scholar 

  49. Fan Y, **e P, Zhang T, et al. Regulation of the stability and transcriptional activity of NFATc4 by ubiquitination. FEBS Lett. 2008;582(29):4008–14.

    PubMed  CAS  Google Scholar 

  50. Mackiewicz U, Maczewski M, Klemenska E, et al. Brief postinfarction calcineurin blockade affects left ventricular remodeling and Ca2+ handling in the rat. J Mol Cell Cardiol. 2010;48(6):1307–15.

    PubMed  CAS  Google Scholar 

  51. Liu Q, Wilkins BJ, Lee YJ, Ichijo H, Molkentin JD. Direct interaction and reciprocal regulation between ASK1 and calcineurin-NFAT control cardiomyocyte death and growth. Mol Cell Biol. 2006;26(10):3785–97.

    PubMed  CAS  Google Scholar 

  52. Liu Q, Sargent MA, York AJ, Molkentin JD. ASK1 regulates cardiomyocyte death but not hypertrophy in transgenic mice. Circ Res. 2009;105(11):1110–7.

    PubMed  CAS  Google Scholar 

  53. Maillet M, Davis J, Auger-Messier M, et al. Heart-specific deletion of CnB1 reveals multiple mechanisms whereby calcineurin regulates cardiac growth and function. J Biol Chem. 2010;285(9):6716–24.

    PubMed  CAS  Google Scholar 

  54. Bueno OF, Lips DJ, Kaiser RA, et al. Calcineurin Abeta gene targeting predisposes the myocardium to acute ischemia-induced apoptosis and dysfunction. Circ Res. 2004;94(1):91–9.

    PubMed  CAS  Google Scholar 

  55. Obasanjo-Blackshire K, Mesquita R, Jabr RI, et al. Calcineurin regulates NFAT-dependent iNOS expression and protection of cardiomyocytes: co-operation with Src tyrosine kinase. Cardiovasc Res. 2006;71(4):672–83.

    PubMed  CAS  Google Scholar 

  56. Heineke J, Auger-Messier M, Correll RN, et al. CIB1 is a regulator of pathological cardiac hypertrophy. Nat Med. 2010;16(8):872–9.

    PubMed  CAS  Google Scholar 

  57. Wang HG, Pathan N, Ethell IM, et al. Ca2+−induced apoptosis through calcineurin dephosphorylation of BAD. Science. 1999;284(5412):339–43.

    PubMed  CAS  Google Scholar 

  58. Cereghetti GM, Stangherlin A, Martins de Brito O, et al. Dephosphorylation by calcineurin regulates translocation of Drp1 to mitochondria. Proc Natl Acad Sci USA. 2008;105(41):15803–8.

    PubMed  CAS  Google Scholar 

  59. Saito S, Hiroi Y, Zou Y, et al. beta-Adrenergic pathway induces apoptosis through calcineurin activation in cardiac myocytes. J Biol Chem. 2000;275(44):34528–33.

    PubMed  CAS  Google Scholar 

  60. Pu WT, Ma Q, Izumo S. NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro. Circ Res. 2003;92(7):725–31.

    PubMed  CAS  Google Scholar 

  61. Mano A, Tatsumi T, Shiraishi J, et al. Aldosterone directly induces myocyte apoptosis through calcineurin-dependent pathways. Circulation. 2004;110(3):317–23.

    PubMed  CAS  Google Scholar 

  62. Maiese K, Hou J, Chong ZZ, Shang YC. A fork in the path: Develo** therapeutic inroads with FoxO proteins. Oxid Med Cell Longev. 2009;2(3):119–29.

    PubMed  Google Scholar 

  63. Ronnebaum SM, Patterson C. The FoxO family in cardiac function and dysfunction. Annu Rev Physiol. 2010;72:81–94.

    PubMed  CAS  Google Scholar 

  64. Tremblay ML, Giguere V. Phosphatases at the heart of FoxO metabolic control. Cell Metab. 2008;7(2):101–3.

    PubMed  CAS  Google Scholar 

  65. Colao A. The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin Endocrinol. 2008;69(3):347–58.

    CAS  Google Scholar 

  66. Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 1997;7(4):261–9.

    PubMed  CAS  Google Scholar 

  67. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307(5712):1098–101.

    PubMed  CAS  Google Scholar 

  68. Meier R, Alessi DR, Cron P, Andjelkovic M, Hemmings BA. Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase Bbeta. J Biol Chem. 1997;272(48):30491–7.

    PubMed  CAS  Google Scholar 

  69. Brownawell AM, Kops GJ, Macara IG, Burgering BM. Inhibition of nuclear import by protein kinase B (Akt) regulates the subcellular distribution and activity of the forkhead transcription factor AFX. Mol Cell Biol. 2001;21(10):3534–46.

    PubMed  CAS  Google Scholar 

  70. Biggs III WH, Meisenhelder J, Hunter T, Cavenee WK, Arden KC. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci USA. 1999;96(13):7421–6.

    PubMed  CAS  Google Scholar 

  71. Brunet A, Kanai F, Stehn J, et al. 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J Cell Biol. 2002;156(5):817–28.

    PubMed  CAS  Google Scholar 

  72. Ivaska J, Nissinen L, Immonen N, Eriksson JE, Kahari VM, Heino J. Integrin alpha 2 beta 1 promotes activation of protein phosphatase 2A and dephosphorylation of Akt and glycogen synthase kinase 3 beta. Mol Cell Biol. 2002;22(5):1352–9.

    PubMed  CAS  Google Scholar 

  73. Ni YG, Wang N, Cao DJ, et al. FoxO transcription factors activate Akt and attenuate insulin signaling in heart by inhibiting protein phosphatases. Proc Natl Acad Sci USA. 2007;104(51):20517–22.

    PubMed  CAS  Google Scholar 

  74. Plas DR, Thompson CB. Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J Biol Chem. 2003;278(14):12361–6.

    PubMed  CAS  Google Scholar 

  75. Huang H, Regan KM, Wang F, et al. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci USA. 2005;102(5):1649–54.

    PubMed  CAS  Google Scholar 

  76. Li F, **e P, Fan Y, et al. C terminus of Hsc70-interacting protein promotes smooth muscle cell proliferation and survival through ubiquitin-mediated degradation of FoxO1. J Biol Chem. 2009;284(30):20090–8.

    PubMed  CAS  Google Scholar 

  77. Yang JY, Zong CS, **a W, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008;10(2):138–48.

    PubMed  CAS  Google Scholar 

  78. Kato S, Ding J, Pisck E, Jhala US, Du K. COP1 functions as a FoxO1 ubiquitin E3 ligase to regulate FoxO1-mediated gene expression. J Biol Chem. 2008;283(51):35464–73.

    PubMed  CAS  Google Scholar 

  79. Brenkman AB, de Keizer PL, van den Broek NJ, Jochemsen AG, Burgering BM. Mdm2 induces mono-ubiquitination of FOXO4. PLoS One. 2008;3(7):e2819.

    PubMed  Google Scholar 

  80. van der Horst A, de Vries-Smits AM, Brenkman AB, et al. FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP. Nat Cell Biol. 2006;8(10):1064–73.

    PubMed  Google Scholar 

  81. Razeghi P, Baskin KK, Sharma S, et al. Atrophy, hypertrophy, and hypoxemia induce transcriptional regulators of the ubiquitin proteasome system in the rat heart. Biochem Biophys Res Commun. 2006;342(2):361–4.

    PubMed  CAS  Google Scholar 

  82. Rommel C, Bodine SC, Clarke BA, et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol. 2001;3(11):1009–13.

    PubMed  CAS  Google Scholar 

  83. Antos CL, McKinsey TA, Frey N, et al. Activated glycogen synthase-3 beta suppresses ­cardiac hypertrophy in vivo. Proc Natl Acad Sci USA. 2002;99(2):907–12.

    PubMed  CAS  Google Scholar 

  84. Skurk C, Izumiya Y, Maatz H, et al. The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem. 2005;280(21):20814–23.

    PubMed  CAS  Google Scholar 

  85. Ni YG, Berenji K, Wang N, et al. Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling. Circulation. 2006;114(11):1159–68.

    PubMed  CAS  Google Scholar 

  86. Kane GC, Behfar A, Dyer RB, et al. KCNJ11 gene knockout of the Kir6.2 KATP channel causes maladaptive remodeling and heart failure in hypertension. Hum Mol Genet. 2006;15(15):2285–97.

    PubMed  CAS  Google Scholar 

  87. Philip-Couderc P, Tavares NI, Roatti A, Lerch R, Montessuit C, Baertschi AJ. Forkhead transcription factors coordinate expression of myocardial KATP channel subunits and energy metabolism. Circ Res. 2008;102(2):e20–35.

    PubMed  CAS  Google Scholar 

  88. Sengupta A, Molkentin JD, Paik JH, DePinho RA, Yutzey KE. FoxO transcription factors promote cardiomyocyte survival upon induction of oxidative stress. J Biol Chem. 2011;286(9):7468–78.

    PubMed  CAS  Google Scholar 

  89. Caporali A, Sala-Newby GB, Meloni M, et al. Identification of the prosurvival activity of nerve growth factor on cardiac myocytes. Cell Death Differ. 2008;15(2):299–311.

    PubMed  CAS  Google Scholar 

  90. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387(6630):299–303.

    PubMed  CAS  Google Scholar 

  91. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997;420(1):25–7.

    PubMed  CAS  Google Scholar 

  92. Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev. 2010;24(15):1580–9.

    PubMed  CAS  Google Scholar 

  93. Sharpless NE, DePinho RA. Telomeres, stem cells, senescence, and cancer. J Clin Invest. 2004;113(2):160–8.

    PubMed  CAS  Google Scholar 

  94. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol. 2001;2(10):731–7.

    PubMed  CAS  Google Scholar 

  95. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 1995;378(6553):206–8.

    PubMed  CAS  Google Scholar 

  96. de Oca M, Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995;378(6553):203–6.

    Google Scholar 

  97. Brooks CL, Gu W. p53 regulation by ubiquitin. FEBS Lett. 2011;585(18):2803–9.

    PubMed  CAS  Google Scholar 

  98. Lohrum MA, Woods DB, Ludwig RL, Balint E, Vousden KH. C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol. 2001;21(24):8521–32.

    PubMed  CAS  Google Scholar 

  99. Rodriguez MS, Desterro JM, Lain S, Lane DP, Hay RT. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol. 2000;20(22):8458–67.

    PubMed  CAS  Google Scholar 

  100. Krummel KA, Lee CJ, Toledo F, Wahl GM. The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc Natl Acad Sci USA. 2005;102(29):10188–93.

    PubMed  CAS  Google Scholar 

  101. Feng L, Lin T, Uranishi H, Gu W, Xu Y. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol. 2005;25(13):5389–95.

    PubMed  CAS  Google Scholar 

  102. Chan WM, Mak MC, Fung TK, Lau A, Siu WY, Poon RY. Ubiquitination of p53 at multiple sites in the DNA-binding domain. Mol Cancer Res. 2006;4(1):15–25.

    PubMed  CAS  Google Scholar 

  103. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science. 2003;302(5652):1972–5.

    PubMed  CAS  Google Scholar 

  104. Ringshausen I, O’Shea CC, Finch AJ, Swigart LB, Evan GI. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell. 2006;10(6):501–14.

    PubMed  CAS  Google Scholar 

  105. McDonough H, Patterson C. CHIP: a link between the chaperone and proteasome systems. Cell Stress Chaperones. 2003;8(4):303–8.

    PubMed  CAS  Google Scholar 

  106. Weger S, Hammer E, Heilbronn R. Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo. FEBS Lett. 2005;579(22):5007–12.

    PubMed  CAS  Google Scholar 

  107. Rajendra R, Malegaonkar D, Pungaliya P, et al. Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitylates p53. J Biol Chem. 2004;279(35):36440–4.

    PubMed  CAS  Google Scholar 

  108. Yang W, Rozan LM, McDonald III ER, et al. CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. J Biol Chem. 2007;282(5):3273–81.

    PubMed  CAS  Google Scholar 

  109. Chen D, Kon N, Li M, Zhang W, Qin J, Gu W. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell. 2005;121(7):1071–83.

    PubMed  CAS  Google Scholar 

  110. Grossman SR, Deato ME, Brignone C, et al. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science. 2003;300(5617):342–4.

    PubMed  CAS  Google Scholar 

  111. Yamasaki S, Yagishita N, Sasaki T, et al. Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase ‘Synoviolin’. EMBO J. 2007;26(1):113–22.

    PubMed  CAS  Google Scholar 

  112. Tasdemir E, Maiuri MC, Galluzzi L, et al. Regulation of autophagy by cytoplasmic p53. Nat Cell Biol. 2008;10(6):676–87.

    PubMed  CAS  Google Scholar 

  113. Marchenko ND, Moll UM. The role of ubiquitination in the direct mitochondrial death program of p53. Cell Cycle. 2007;6(14):1718–23.

    PubMed  CAS  Google Scholar 

  114. Marchenko ND, Wolff S, Erster S, Becker K, Moll UM. Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J. 2007;26(4):923–34.

    PubMed  CAS  Google Scholar 

  115. Tomita Y, Marchenko N, Erster S, et al. WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem. 2006;281(13):8600–6.

    PubMed  CAS  Google Scholar 

  116. Chipuk JE, Kuwana T, Bouchier-Hayes L, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004;303(5660):1010–4.

    PubMed  CAS  Google Scholar 

  117. Mihara M, Erster S, Zaika A, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 2003;11(3):577–90.

    PubMed  CAS  Google Scholar 

  118. Chatterjee A, Mir SA, Dutta D, Mitra A, Pathak K, Sarkar S. Analysis of p53 and NF-kappaB signaling in modulating the cardiomyocyte fate during hypertrophy. J Cell Physiol. 2011;226(10):2543–54.

    PubMed  CAS  Google Scholar 

  119. Sano M, Minamino T, Toko H, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature. 2007;446(7134):444–8.

    PubMed  CAS  Google Scholar 

  120. Birks EJ, Latif N, Enesa K, et al. Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy. Cardiovasc Res. 2008;79(3):472–80.

    PubMed  CAS  Google Scholar 

  121. Naito AT, Okada S, Minamino T, et al. Promotion of CHIP-mediated p53 degradation protects the heart from ischemic injury. Circ Res. 2010;106(11):1692–702.

    PubMed  CAS  Google Scholar 

  122. Kimata M, Matoba S, Iwai-Kanai E, et al. p53 and TIGAR regulate cardiac myocyte energy homeostasis under hypoxic stress. Am J Physiol Heart Circ Physiol. 2010;299(6):H1908–16.

    PubMed  CAS  Google Scholar 

  123. Fiordaliso F, Leri A, Cesselli D, et al. Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death. Diabetes. 2001;50(10):2363–75.

    PubMed  CAS  Google Scholar 

  124. Kobayashi S, Mao K, Zheng H, et al. Diminished GATA4 protein levels contribute to hyperglycemia-induced cardiomyocyte injury. J Biol Chem. 2007;282(30):21945–52.

    PubMed  CAS  Google Scholar 

  125. Couse JF, Lindzey J, Grandien K, Gustafsson JA, Korach KS. Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. Endocrinology. 1997;138(11):4613–21.

    PubMed  CAS  Google Scholar 

  126. Grohe C, Kahlert S, Lobbert K, Vetter H. Expression of oestrogen receptor alpha and beta in rat heart: role of local oestrogen synthesis. J Endocrinol. 1998;156(2):R1–7.

    PubMed  CAS  Google Scholar 

  127. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340(23):1801–11.

    PubMed  CAS  Google Scholar 

  128. Jankowski M, Rachelska G, Donghao W, McCann SM, Gutkowska J. Estrogen receptors activate atrial natriuretic peptide in the rat heart. Proc Natl Acad Sci USA. 2001;98(20):11765–70.

    PubMed  CAS  Google Scholar 

  129. Nilsson S, Makela S, Treuter E, et al. Mechanisms of estrogen action. Physiol Rev. 2001;81(4):1535–65.

    PubMed  CAS  Google Scholar 

  130. Klinge CM. Estrogen receptor interaction with co-activators and co-repressors. Steroids. 2000;65(5):227–51.

    PubMed  CAS  Google Scholar 

  131. Ruff M, Gangloff M, Wurtz JM, Moras D. Estrogen receptor transcription and transactivation: structure-function relationship in DNA- and ligand-binding domains of estrogen receptors. Breast Cancer Res. 2000;2(5):353–9.

    PubMed  CAS  Google Scholar 

  132. van der Vaart M, Schaaf MJ. Naturally occurring C-terminal splice variants of nuclear receptors. Nucl Recept Signal. 2009;7:e007.

    PubMed  Google Scholar 

  133. Rosenfeld MG, Glass CK. Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem. 2001;276(40):36865–8.

    PubMed  CAS  Google Scholar 

  134. Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiol Rev. 2001;81(3):1269–304.

    PubMed  CAS  Google Scholar 

  135. Leitman DC, Paruthiyil S, Vivar OI, et al. Regulation of specific target genes and biological responses by estrogen receptor subtype agonists. Curr Opin Pharmacol. 2010;10(6):629–36.

    PubMed  CAS  Google Scholar 

  136. Gottlicher M, Heck S, Herrlich P. Transcriptional cross-talk, the second mode of steroid hormone receptor action. J Mol Med. 1998;76(7):480–9.

    PubMed  CAS  Google Scholar 

  137. Kousteni S, Bellido T, Plotkin LI, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 2001;104(5):719–30.

    PubMed  CAS  Google Scholar 

  138. Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C. Peroxisome proliferator-activated receptor alpha (PPARalpha ) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes. J Biol Chem. 2002;277(40):37254–9.

    PubMed  CAS  Google Scholar 

  139. Dace A, Zhao L, Park KS, et al. Hormone binding induces rapid proteasome-mediated degradation of thyroid hormone receptors. Proc Natl Acad Sci USA. 2000;97(16):8985–90.

    PubMed  CAS  Google Scholar 

  140. Boudjelal M, Wang Z, Voorhees JJ, Fisher GJ. Ubiquitin/proteasome pathway regulates levels of retinoic acid receptor gamma and retinoid X receptor alpha in human keratinocytes. Cancer Res. 2000;60(8):2247–52.

    PubMed  CAS  Google Scholar 

  141. Lee JW, Ryan F, Swaffield JC, Johnston SA, Moore DD. Interaction of thyroid-hormone receptor with a conserved transcriptional mediator. Nature. 1995;374(6517):91–4.

    PubMed  CAS  Google Scholar 

  142. Imhof MO, McDonnell DP. Yeast RSP5 and its human homolog hRPF1 potentiate hormone-dependent activation of transcription by human progesterone and glucocorticoid receptors. Mol Cell Biol. 1996;16(6):2594–605.

    PubMed  CAS  Google Scholar 

  143. Nawaz Z, Lonard DM, Smith CL, et al. The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol Cell Biol. 1999;19(2):1182–9.

    PubMed  CAS  Google Scholar 

  144. Poukka H, Aarnisalo P, Karvonen U, Palvimo JJ, Janne OA. Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription. J Biol Chem. 1999;274(27):19441–6.

    PubMed  CAS  Google Scholar 

  145. Eckert RL, Mullick A, Rorke EA, Katzenellenbogen BS. Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by a density shift technique. Endocrinology. 1984;114(2):629–37.

    PubMed  CAS  Google Scholar 

  146. Alarid ET, Bakopoulos N, Solodin N. Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. Mol Endocrinol. 1999;13(9):1522–34.

    PubMed  CAS  Google Scholar 

  147. Devin-Leclerc J, Meng X, Delahaye F, Leclerc P, Baulieu EE, Catelli MG. Interaction and dissociation by ligands of estrogen receptor and Hsp90: the antiestrogen RU 58668 induces a protein synthesis-dependent clustering of the receptor in the cytoplasm. Mol Endocrinol. 1998;12(6):842–54.

    PubMed  CAS  Google Scholar 

  148. Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA. 1992;89(9):4037–41.

    PubMed  CAS  Google Scholar 

  149. Magro EM, Martinez JM. Statistical trial of succinylcholine. Rev Esp Anestesiol Reanim. 1975;22(1):1–35.

    PubMed  CAS  Google Scholar 

  150. Laios I, Journe F, Laurent G, et al. Mechanisms governing the accumulation of estrogen receptor alpha in MCF-7 breast cancer cells treated with hydroxytamoxifen and related antiestrogens. J Steroid Biochem Mol Biol. 2003;87(2–3):207–21.

    PubMed  CAS  Google Scholar 

  151. Alarid ET, Preisler-Mashek MT, Solodin NM. Thyroid hormone is an inhibitor of estrogen-induced degradation of estrogen receptor-alpha protein: estrogen-dependent proteolysis is not essential for receptor transactivation function in the pituitary. Endocrinology. 2003;144(8):3469–76.

    PubMed  CAS  Google Scholar 

  152. Tsai KS, Yang RS, Liu SH. Benzo[a]pyrene regulates osteoblast proliferation through an estrogen receptor-related cyclooxygenase-2 pathway. Chem Res Toxicol. 2004;17(5):679–84.

    PubMed  CAS  Google Scholar 

  153. Galigniana MD, Harrell JM, Housley PR, Patterson C, Fisher SK, Pratt WB. Retrograde transport of the glucocorticoid receptor in neurites requires dynamic assembly of complexes with the protein chaperone hsp90 and is linked to the CHIP component of the machinery for proteasomal degradation. Brain Res Mol Brain Res. 2004;123(1–2):27–36.

    PubMed  CAS  Google Scholar 

  154. Stenoien DL, Nye AC, Mancini MG, et al. Ligand-mediated assembly and real-time cellular dynamics of estrogen receptor alpha-coactivator complexes in living cells. Mol Cell Biol. 2001;21(13):4404–12.

    PubMed  CAS  Google Scholar 

  155. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell. 2000;103(6):843–52.

    PubMed  CAS  Google Scholar 

  156. Reid G, Hubner MR, Metivier R, et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell. 2003;11(3):695–707.

    PubMed  CAS  Google Scholar 

  157. Fan M, Park A, Nephew KP. CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha. Mol Endocrinol. 2005;19(12):2901–14.

    PubMed  CAS  Google Scholar 

  158. Dai Q, Zhang C, Wu Y, et al. CHIP activates HSF1 and confers protection against apoptosis and cellular stress. EMBO J. 2003;22(20):5446–58.

    PubMed  CAS  Google Scholar 

  159. Ballinger CA, Connell P, Wu Y, et al. Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol Cell Biol. 1999;19(6):4535–45.

    PubMed  CAS  Google Scholar 

  160. Tateishi Y, Kawabe Y, Chiba T, et al. Ligand-dependent switching of ubiquitin-proteasome pathways for estrogen receptor. EMBO J. 2004;23(24):4813–23.

    PubMed  CAS  Google Scholar 

  161. Nordmeyer J, Eder S, Mahmoodzadeh S, et al. Upregulation of myocardial estrogen receptors in human aortic stenosis. Circulation. 2004;110(20):3270–5.

    PubMed  CAS  Google Scholar 

  162. Hayward CS, Kalnins WV, Kelly RP. Acute effects of 17beta-estradiol on ventricular and vascular hemodynamics in postmenopausal women. Am J Physiol Heart Circ Physiol. 2000;279(5):H2277–84.

    PubMed  CAS  Google Scholar 

  163. Patten RD, Pourati I, Aronovitz MJ, et al. 17 Beta-estradiol differentially affects left ventricular and cardiomyocyte hypertrophy following myocardial infarction and pressure overload. J Card Fail. 2008;14(3):245–53.

    PubMed  CAS  Google Scholar 

  164. van Eickels M, Grohe C, Cleutjens JP, Janssen BJ, Wellens HJ, Doevendans PA. 17beta-estradiol attenuates the development of pressure-overload hypertrophy. Circulation. 2001;104(12):1419–23.

    PubMed  Google Scholar 

  165. Donaldson C, Eder S, Baker C, et al. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation. Circ Res. 2009;104(2):265–75. 211p following 275.

    PubMed  CAS  Google Scholar 

  166. Fliegner D, Schubert C, Penkalla A, et al. Female sex and estrogen receptor-beta attenuate cardiac remodeling and apoptosis in pressure overload. Am J Physiol Regul Integr Comp Physiol. 2010;298(6):R1597–606.

    PubMed  CAS  Google Scholar 

  167. Pedram A, Razandi M, Lubahn D, Liu J, Vannan M, Levin ER. Estrogen inhibits cardiac hypertrophy: role of estrogen receptor-beta to inhibit calcineurin. Endocrinology. 2008;149(7):3361–9.

    PubMed  CAS  Google Scholar 

  168. Skavdahl M, Steenbergen C, Clark J, et al. Estrogen receptor-beta mediates male–female differences in the development of pressure overload hypertrophy. Am J Physiol Heart Circ Physiol. 2005;288(2):H469–76.

    PubMed  CAS  Google Scholar 

  169. Kararigas G, Fliegner D, Gustafsson JA, Regitz-Zagrosek V. Role of the estrogen/estrogen-receptor-beta axis in the genomic response to pressure overload-induced hypertrophy. Physiol Genomics. 2011;43(8):438–46.

    PubMed  CAS  Google Scholar 

  170. Deschamps AM, Murphy E, Sun J. Estrogen receptor activation and cardioprotection in ischemia reperfusion injury. Trends Cardiovasc Med. 2010;20(3):73–8.

    PubMed  CAS  Google Scholar 

  171. Baker L, Meldrum KK, Wang M, et al. The role of estrogen in cardiovascular disease. J Surg Res. 2003;115(2):325–44.

    PubMed  CAS  Google Scholar 

  172. Zhai P, Eurell TE, Cotthaus RP, Jeffery EH, Bahr JM, Gross DR. Effects of dietary phytoestrogen on global myocardial ischemia-reperfusion injury in isolated female rat hearts. Am J Physiol Heart Circ Physiol. 2001;281(3):H1223–32.

    PubMed  CAS  Google Scholar 

  173. Angele MK, Schwacha MG, Ayala A, Chaudry IH. Effect of gender and sex hormones on immune responses following shock. Shock. 2000;14(2):81–90.

    PubMed  CAS  Google Scholar 

  174. Vornehm ND, Wang M, Abarbanell A, et al. Acute postischemic treatment with estrogen receptor-alpha agonist or estrogen receptor-beta agonist improves myocardial recovery. Surgery. 2009;146(2):145–54.

    PubMed  Google Scholar 

  175. Booth EA, Obeid NR, Lucchesi BR. Activation of estrogen receptor-alpha protects the in vivo rabbit heart from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2005;289(5):H2039–47.

    PubMed  CAS  Google Scholar 

  176. Jeanes HL, Tabor C, Black D, Ederveen A, Gray GA. Oestrogen-mediated cardioprotection following ischaemia and reperfusion is mimicked by an oestrogen receptor (ER)alpha agonist and unaffected by an ER beta antagonist. J Endocrinol. 2008;197(3):493–501.

    PubMed  CAS  Google Scholar 

  177. Wang M, Crisostomo P, Wairiuko GM, Meldrum DR. Estrogen receptor-alpha mediates acute myocardial protection in females. Am J Physiol Heart Circ Physiol. 2006;290(6):H2204–9.

    PubMed  CAS  Google Scholar 

  178. Babiker FA, Lips DJ, Delvaux E, et al. Oestrogen modulates cardiac ischaemic remodelling through oestrogen receptor-specific mechanisms. Acta Physiol (Oxf). 2007;189(1):23–31.

    CAS  Google Scholar 

  179. Gabel SA, Walker VR, London RE, Steenbergen C, Korach KS, Murphy E. Estrogen receptor beta mediates gender differences in ischemia/reperfusion injury. J Mol Cell Cardiol. 2005;38(2):289–97.

    PubMed  CAS  Google Scholar 

  180. Wang M, Crisostomo PR, Markel T, Wang Y, Lillemoe KD, Meldrum DR. Estrogen receptor beta mediates acute myocardial protection following ischemia. Surgery. 2008;144(2):233–8.

    PubMed  Google Scholar 

  181. Wang M, Wang Y, Weil B, et al. Estrogen receptor beta mediates increased activation of PI3K/Akt signaling and improved myocardial function in female hearts following acute ischemia. Am J Physiol Regul Integr Comp Physiol. 2009;296(4):R972–8.

    PubMed  CAS  Google Scholar 

  182. Liu H, Pedram A, Kim JK. Oestrogen prevents cardiomyocyte apoptosis by suppressing p38alpha-mediated activation of p53 and by down-regulating p53 inhibition on p38beta. Cardiovasc Res. 2011;89(1):119–28.

    PubMed  CAS  Google Scholar 

  183. Hatada EN, Krappmann D, Scheidereit C. NF-kappaB and the innate immune response. Curr Opin Immunol. 2000;12(1):52–8.

    PubMed  CAS  Google Scholar 

  184. Karin M, Delhase M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol. 2000;12(1):85–98.

    PubMed  CAS  Google Scholar 

  185. Medzhitov R, Janeway Jr C. Innate immune recognition: mechanisms and pathways. Immunol Rev. 2000;173:89–97.

    PubMed  CAS  Google Scholar 

  186. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994;78(5):773–85.

    PubMed  CAS  Google Scholar 

  187. Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol. 2005;7(8):758–65.

    PubMed  CAS  Google Scholar 

  188. Moynagh PN. The NF-kappaB pathway. J Cell Sci. 2005;118(Pt 20):4589–92.

    PubMed  CAS  Google Scholar 

  189. Hoffmann A, Natoli G, Ghosh G. Transcriptional regulation via the NF-kappaB signaling module. Oncogene. 2006;25(51):6706–16.

    PubMed  CAS  Google Scholar 

  190. Skaug B, Jiang X, Chen ZJ. The role of ubiquitin in NF-kappaB regulatory pathways. Annu Rev Biochem. 2009;78:769–96.

    PubMed  CAS  Google Scholar 

  191. Gilmore TD. The Rel/NF-kappaB signal transduction pathway: introduction. Oncogene. 1999;18(49):6842–4.

    PubMed  CAS  Google Scholar 

  192. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 2006;25(51):6680–4.

    PubMed  CAS  Google Scholar 

  193. Maniatis T. A ubiquitin ligase complex essential for the NF-kappaB, Wnt/Wingless, and Hedgehog signaling pathways. Genes Dev. 1999;13(5):505–10.

    PubMed  CAS  Google Scholar 

  194. Chinnaiyan AM, O’Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell. 1995;81(4):505–12.

    PubMed  CAS  Google Scholar 

  195. Verstrepen L, Bekaert T, Chau TL, Tavernier J, Chariot A, Beyaert R. TLR-4, IL-1R and TNF-R signaling to NF-kappaB: variations on a common theme. Cell Mol Life Sci. 2008;65(19):2964–78.

    PubMed  CAS  Google Scholar 

  196. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol. 1994;10:405–55.

    PubMed  CAS  Google Scholar 

  197. Shaw J, Yurkova N, Zhang T, et al. Antagonism of E2F-1 regulated Bnip3 transcription by NF-kappaB is essential for basal cell survival. Proc Natl Acad Sci USA. 2008;105(52):20734–9.

    PubMed  CAS  Google Scholar 

  198. Brockman JA, Scherer DC, McKinsey TA, et al. Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation. Mol Cell Biol. 1995;15(5):2809–18.

    PubMed  CAS  Google Scholar 

  199. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science. 1995;267(5203):1485–8.

    PubMed  CAS  Google Scholar 

  200. Hoffmann A, Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol Rev. 2006;210:171–86.

    PubMed  Google Scholar 

  201. Arenzana-Seisdedos F, Turpin P, Rodriguez M, et al. Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm. J Cell Sci. 1997;110(Pt 3):369–78.

    PubMed  CAS  Google Scholar 

  202. Pye J, Ardeshirpour F, McCain A, et al. Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol. 2003;284(3):H919–26.

    PubMed  CAS  Google Scholar 

  203. Stansfield WE, Moss NC, Willis MS, Tang R, Selzman CH. Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-­reperfusion injury. Ann Thorac Surg. 2007;84(1):120–5.

    PubMed  Google Scholar 

  204. Yu X, Kem DC. Proteasome inhibition during myocardial infarction. Cardiovasc Res. 2010;85(2):312–20.

    PubMed  CAS  Google Scholar 

  205. Depre C, Wang Q, Yan L, et al. Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation. 2006;114(17):1821–8.

    PubMed  CAS  Google Scholar 

  206. Hedhli N, Lizano P, Hong C, et al. Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload. Am J Physiol Heart Circ Physiol. 2008;295(4):H1385–93.

    PubMed  CAS  Google Scholar 

  207. Stansfield WE, Tang RH, Moss NC, Baldwin AS, Willis MS, Selzman CH. Proteasome inhibition promotes regression of left ventricular hypertrophy. Am J Physiol Heart Circ Physiol. 2008;294(2):H645–50.

    PubMed  CAS  Google Scholar 

  208. Ma Y, Chen B, Liu D, et al. MG132 treatment attenuates cardiac remodeling and dysfunction following aortic banding in rats via the NF-kappaB/TGFbeta1 pathway. Biochem Pharmacol. 2011;81(10):1228–36.

    PubMed  CAS  Google Scholar 

  209. Itoh S, Itoh F, Goumans MJ, Ten Dijke P. Signaling of transforming growth factor-beta family members through Smad proteins. Eur J Biochem/FEBS. 2000;267(24):6954–67.

    CAS  Google Scholar 

  210. Herpin A, Lelong C, Favrel P. Transforming growth factor-beta-related proteins: an ancestral and widespread superfamily of cytokines in metazoans. Dev Comp Immunol. 2004;28(5):461–85.

    PubMed  CAS  Google Scholar 

  211. Koinuma D, Shinozaki M, Komuro A, et al. Arkadia amplifies TGF-beta superfamily signalling through degradation of Smad7. EMBO J. 2003;22(24):6458–70.

    PubMed  CAS  Google Scholar 

  212. Nagano Y, Mavrakis KJ, Lee KL, et al. Arkadia induces degradation of SnoN and c-Ski to enhance transforming growth factor-beta signaling. J Biol Chem. 2007;282(28):20492–501.

    PubMed  CAS  Google Scholar 

  213. Liu W, Rui H, Wang J, et al. Axin is a scaffold protein in TGF-beta signaling that promotes degradation of Smad7 by Arkadia. EMBO J. 2006;25(8):1646–58.

    PubMed  CAS  Google Scholar 

  214. Moustakas A, Souchelnytskyi S, Heldin CH. Smad regulation in TGF-beta signal transduction. J Cell Sci. 2001;114(Pt 24):4359–69.

    PubMed  CAS  Google Scholar 

  215. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425(6958):577–84.

    PubMed  CAS  Google Scholar 

  216. Inoue Y, Imamura T. Regulation of TGF-beta family signaling by E3 ubiquitin ligases. Cancer Sci. 2008;99(11):2107–12.

    PubMed  CAS  Google Scholar 

  217. Ingham RJ, Gish G, Pawson T. The Nedd4 family of E3 ubiquitin ligases: functional diversity within a common modular architecture. Oncogene. 2004;23(11):1972–84.

    PubMed  CAS  Google Scholar 

  218. Kim BG, Lee JH, Yasuda J, Ryoo HM, Cho JY. Phospho-Smad1 modulation by nedd4 E3 ligase in BMP/TGF-beta signaling. J Bone Miner Res. 2011;26(7):1411–24.

    PubMed  CAS  Google Scholar 

  219. **n H, Xu X, Li L, et al. CHIP controls the sensitivity of transforming growth factor-beta signaling by modulating the basal level of Smad3 through ubiquitin-mediated degradation. J Biol Chem. 2005;280(21):20842–50.

    PubMed  CAS  Google Scholar 

  220. Fouladkou F, Lu C, Jiang C, et al. The ubiquitin ligase Nedd4-1 is required for heart development and is a suppressor of thrombospondin-1. J Biol Chem. 2010;285(9):6770–80.

    PubMed  CAS  Google Scholar 

  221. Shi PP, Cao XR, Sweezer EM, et al. Salt-sensitive hypertension and cardiac hypertrophy in mice deficient in the ubiquitin ligase Nedd4-2. Am J Physiol Renal Physiol. 2008;295(2):F462–70.

    PubMed  CAS  Google Scholar 

  222. Wang B, Hao J, Jones SC, Yee MS, Roth JC, Dixon IM. Decreased Smad 7 expression contributes to cardiac fibrosis in the infarcted rat heart. Am J Physiol Heart Circ Physiol. 2002;282(5):H1685–96.

    PubMed  CAS  Google Scholar 

  223. Wang B, Omar A, Angelovska T, et al. Regulation of collagen synthesis by inhibitory Smad7 in cardiac myofibroblasts. Am J Physiol Heart Circ Physiol. 2007;293(2):H1282–90.

    PubMed  CAS  Google Scholar 

  224. Chen Q, Chen H, Zheng D, et al. Smad7 is required for the development and function of the heart. J Biol Chem. 2009;284(1):292–300.

    PubMed  CAS  Google Scholar 

  225. Yuzawa H, Koinuma D, Maeda S, Yamamoto K, Miyazawa K, Imamura T. Arkadia represses the expression of myoblast differentiation markers through degradation of Ski and the Ski-bound Smad complex in C2C12 myoblasts. Bone. 2009;44(1):53–60.

    PubMed  CAS  Google Scholar 

  226. Zhang C, Xu Z, He XR, Michael LH, Patterson C. CHIP, a cochaperone/ubiquitin ligase that regulates protein quality control, is required for maximal cardioprotection after myocardial infarction in mice. Am J Physiol Heart Circ Physiol. 2005;288(6):H2836–42.

    PubMed  CAS  Google Scholar 

  227. Sakata Y, Chancey AL, Divakaran VG, Sekiguchi K, Sivasubramanian N, Mann DL. Transforming growth factor-beta receptor antagonism attenuates myocardial fibrosis in mice with cardiac-restricted overexpression of tumor necrosis factor. Basic Res Cardiol. 2008;103(1):60–8.

    PubMed  CAS  Google Scholar 

  228. Heger J, Peters SC, Piper HM, Euler G. SMAD-proteins as a molecular switch from hypertrophy to apoptosis induction in adult ventricular cardiomyocytes. J Cell Physiol. 2009;220(2):515–23.

    PubMed  CAS  Google Scholar 

  229. Schneiders D, Heger J, Best P, Michael Piper H, Taimor G. SMAD proteins are involved in apoptosis induction in ventricular cardiomyocytes. Cardiovasc Res. 2005;67(1):87–96.

    PubMed  CAS  Google Scholar 

  230. **a Y, Lee K, Li N, Corbett D, Mendoza L, Frangogiannis NG. Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload. Histochem Cell Biol. 2009;131(4):471–81.

    PubMed  CAS  Google Scholar 

  231. Zhao XY, Zhao LY, Zheng QS, et al. Chymase induces profibrotic response via transforming growth factor-beta 1/Smad activation in rat cardiac fibroblasts. Mol Cell Biochem. 2008;310(1–2):159–66.

    PubMed  CAS  Google Scholar 

  232. Divakaran V, Adrogue J, Ishiyama M, et al. Adaptive and maladaptive effects of SMAD3 signaling in the adult heart after hemodynamic pressure overloading. Circ Heart Fail. 2009;2(6):633–42.

    PubMed  CAS  Google Scholar 

  233. Cucoranu I, Clempus R, Dikalova A, et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res. 2005;97(9):900–7.

    PubMed  CAS  Google Scholar 

  234. Hao J, Ju H, Zhao S, Junaid A, Scammell-La Fleur T, Dixon IM. Elevation of expression of Smads 2, 3, and 4, decorin and TGF-beta in the chronic phase of myocardial infarct scar healing. J Mol Cell Cardiol. 1999;31(3):667–78.

    PubMed  CAS  Google Scholar 

  235. Hao J, Wang B, Jones SC, Jassal DS, Dixon IM. Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro. Am J Physiol Heart Circ Physiol. 2000;279(6):H3020–30.

    PubMed  CAS  Google Scholar 

  236. Masaki M, Izumi M, Oshima Y, et al. Smad1 protects cardiomyocytes from ischemia-reperfusion injury. Circulation. 2005;111(21):2752–9.

    PubMed  CAS  Google Scholar 

  237. Euler-Taimor G, Heger J. The complex pattern of SMAD signaling in the cardiovascular system. Cardiovasc Res. 2006;69(1):15–25.

    PubMed  CAS  Google Scholar 

  238. West J. Cross talk between Smad, MAPK, and actin in the etiology of pulmonary arterial hypertension. Adv Exp Med Biol. 2010;661:265–78.

    PubMed  CAS  Google Scholar 

  239. Yamada M, Szendro PI, Prokscha A, Schwartz RJ, Eichele G. Evidence for a role of Smad6 in chick cardiac development. Dev Biol. 1999;215(1):48–61.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors’ laboratories and training are supported by the National Institutes of Health (R01HL104129 to M.W., R37HL065619 to C.P., T32HL069768 to W.H.D.T.T.).

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, McAllister Heart Institute, University of North Carolina, Medical Biomolecular Research Building, Rm 2336, 103 Mason Farm Road, Chapel Hill, NC, 27599, USA

    Monte S. Willis

  2. McAllister Heart Institute, University of North Carolina, Chapel Hill, NC, USA

    Andrea Portbury & Sarah Ronnebaum

  3. Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA

    Makhosazane Zungu

  4. Department of Cell and Developmental Biology, McAllister Heart Institute, University of North Carolina, Chapel Hill, NC, USA

    W. H. Davin Townley-Tilson

  5. Department of Internal Medicine, Division of Cardiology, McAllister Heart Institute, University of North Carolina, Chapel Hill, NC, USA

    Cam Patterson

Authors
  1. Monte S. Willis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Portbury
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sarah Ronnebaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Makhosazane Zungu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W. H. Davin Townley-Tilson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cam Patterson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monte S. Willis .

Editor information

Editors and Affiliations

  1. , The University of North Carolina, McAllister Heart Institute, 6022 - Burnett Womack Building, Chapel Hill, 27599-7075, North Carolina, USA

    Cam Patterson

  2. , The University of North Carolina, McAllister Heart Institute, 103 Mason Farm Road, Chapel Hill, 27599-7525, USA

    Monte S. Willis

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Willis, M.S., Portbury, A., Ronnebaum, S., Zungu, M., Townley-Tilson, W.H.D., Patterson, C. (2012). Ubiquitylation - Dependent Signaling in Heart Disease. In: Patterson, C., Willis, M. (eds) Translational Cardiology. Molecular and Translational Medicine. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-891-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-891-7_8

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61779-890-0

  • Online ISBN: 978-1-61779-891-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation